Economic burden of inflammatory bowel disease: a UK perspective

References

• Bodger K, Daly MJ, Heatley RV, Williams DRR. Clinical economics in gastroenterology. In: Clinical Economics in Gastroenterology, 1st Edition. Bodger K, Daly MJ, Heatley RV (Eds). Blackwell Science Ltd, Oxford, UK, 1–11 (2000).
   Google Scholar
• Forbes A. Clinical presentations. In: Clinicians’ Guide to Inflammatory Bowel Disease. Forbes A (Ed.). Chapman & Hall Medical, London, UK, 45–85 (1997).
   Google Scholar
• Calkins B, Mendeloff A. Epidemiology of inflammatory bowel disease. Epidemiol. Rev.8, 60–91 (1986).
   PubMed Web of Science ®Google Scholar
• Jewell DP. Ulcerative Colitis. In: Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, PA, USA, 1735 (1998).
   Google Scholar
• Stowe S, Redmond S, Stormont J et al. An epidemiologic study of inflammatory bowel disease in Rochester, New York. Gastroenterology98, 104–116 (1990).
   PubMed Web of Science ®Google Scholar
• Ranzi T, Bodini P, Zambelli A et al. Epidemiological aspects of inflammatory bowel disease in a north Italian population: a 4 year prospective study. Eur. J. Gastroenterol. Hepatol.8, 657–661 (1996).
   PubMedGoogle Scholar
• Srivastava ED, Mayberry JF, Morris TJ et al. Incidence of ulcerative colitis in Cardiff over 20 years: 1968–87. Gut33, 256–258 (1992).
   PubMed Web of Science ®Google Scholar
• Gower-Rousseau C, Salomez J-L, Dupas J-L et al. Incidence of inflammatory bowel disease in northern France (1988–1990). Gut35, 1433–1438 (1994).
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Nielson OH et al. Incidence and prevalence of Crohn`s disease in the county of Copenhagen, 1962–87: a sixfold increase in incidence. Scand. J. Gastroenterol.27, 609–614 (1992).
   PubMed Web of Science ®Google Scholar
• Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease. Scand. J. Gastroenterol.31, 417–427 (1996).
   PubMed Web of Science ®Google Scholar
• Calkins BM; Lilienfeld AM; Garland CF; Mendeloff AI. Trends in incidence rates of ulcerative colitis and Crohn’s disease. Dig. Dis. Sci.29(10), 913–920 (1984).
   PubMed Web of Science ®Google Scholar
• Eisen GM, Sandler RS. Update on the epidemiology of IBD. Prog. Inflamm. Bowel Dis.15, 1–8 (1994).
   Google Scholar
• Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment. Pharmacol. Ther.14(12), 1553–1559 (2000).
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Loftus EV, Sandborn WJ et al. Clinical course and costs of care for Crohn`s disease: Markov model analysis of a population-based cohort. Gastroenterology117, 49–57 (1999).
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology107, 3–11 (1994).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Vermeire S, Rutgeerts P. Medical treatment of inflammatory bowel diseases. Curr. Opin. Gastroenterol.21(4), 443–447 (2005).
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lemann M et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut55(Suppl 1), i16–i35 (2006).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord.3(2), 81–92 (2003).
   PubMedGoogle Scholar
• Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn`s disease. Gastroenterology108, 1056–1067 (1995).
   PubMed Web of Science ®Google Scholar
• Bell SJ, Kamm MA. Review Article: The clinical role of anti-TNFα antibody treatment in crohn’s disease. Aliment. Pharmacol. Ther.14, 501–514 (2004).
   Google Scholar
• Yacyshyn BR. New biotechnological therapies for Crohn`s disease: Where are we now? BioDrugs10(4), 301–316 (1998).
   Google Scholar
• Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. Br. Med. J.320(7245), 1335 (2000).
   PubMed Web of Science ®Google Scholar
• Finkler SA. The distinction between costs and charges. Ann. Intern Med96(1), 102–109 (1982).
   PubMed Web of Science ®Google Scholar
• Schulman K, Burke J, Drummond MF et al. Resource costing for multinational neurological trials. Health Econ.7, 629–638 (1998).
   PubMed Web of Science ®Google Scholar
• Blomqvist P, Ekbom A. Inflammatory bowel disease: health care and costs in Sweden in 1994. Scand. J. Gastrenterol.32, 1134–1139 (1997).
   PubMed Web of Science ®Google Scholar
• Pinchbeck BR, Kirdeikis J, Thompson ABR. Economic impact of inflammatory bowel disease in Alberta. Can. J. Gastroenterol.2(2), 53–56 (1988).
   Google Scholar
• Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J. Clin. Gastroenterol.14(4), 309–317 (1992).
   PubMed Web of Science ®Google Scholar
• Spivak W, Sockolow R, Rigas A. The relationship between insurance class and severity of presentation of inflammatory bowel disease in children. Am. J. Gastroenterol.90(6), 982–987 (1995).
   Google Scholar
• Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: A payor perspective. Am. J. Gastroenterol.95, 1955–1960 (2000).
   PubMed Web of Science ®Google Scholar
• Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut53, 1471–1478 (2004).
   PubMed Web of Science ®Google Scholar
• Jewell DP, Satsangi J, Lobo A et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur. J. Gastroenterol. Hepatol.17(10), 1047–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Hay JW, Hay AR. Inflammatory bowel disease: medical cost algorithms. J. Clin. Gastroenterol.14(4), 318–327 (1992).
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am. J. Gastroenterol.99(4), 650–655 (2004).
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Wu L, Bernstein CN. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am. J. Gastroenterol.98(4), 844–849 (2003).
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am. J. Gastroenterol.98(5), 1064–1072 (2003).
   PubMed Web of Science ®Google Scholar
• Boonen A, Dagnelie PC, Feleus A et al. The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study. Inflamm. Bowel Dis.8(6), 382–389 (2002).
   PubMed Web of Science ®Google Scholar
• Probert CSJ, Mayberry JF. Inflammatory bowel disease; patient expectations in the 1990’s. J. Soc. Med.84, 131–132 (1991).
   Google Scholar
• Moody GA, Mayberry JF. Life insurance and inflammatory bowel disease: is there discrimination against patients? International J. Colorect. Dis.11, 276–278 (1996).
   Google Scholar
• Beck T, Leddin DJ, Lemire SE et al. Insurance rating of patients with inflammatory bowel disease: report of a conference on morbidity and mortality. Can. J. Gastroenterol8(7), (1994).
   Google Scholar
• Russel MG, Ryan BM, Dagnelie PC et al. Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. Gut52(3), 358–362 (2003).
   Google Scholar
• Bodger K. Economic implications of biological therapies for Crohn’s disease: review of infliximab. Pharmacoeconomics23(9), 875–888 (2005).
   PubMedGoogle Scholar
• Hanauer SB, Cohen RD, Becker RV, III, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin. Ther.20, 1009–1028 (1998).
   PubMedGoogle Scholar
• Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J. Clin. Gastroenterol.35, 151–156 (2002).
   PubMed Web of Science ®Google Scholar
• Clark W, Raftery J, Song F et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol. Assess.7, 1–67 (2003).
   PubMedGoogle Scholar
• Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int. J. Technol. Assess. Health Care20, 274–279 (2004).
   PubMed Web of Science ®Google Scholar
• Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology120, 1640–1656 (2001).
   PubMed Web of Science ®Google Scholar
• Dodd S, Bassi A, Bodger K, Williamson P. A comparison of multivariable regression models to analyse cost data. J. Eval. Clin. Pract.12(1), 76–86 (2006).
   PubMed Web of Science ®Google Scholar